$ACHR Korean Air Selects Archer as its Exclusive Partner to Introduce eVTOL Aircraft in Korea

$RAPT T1

Behind the curtain of “charity,” the same elite networks pull every string — shaping education, media, and policy from the top down. When philanthropy becomes theater, democracy takes a back seat.

$REPL ~10% more locked in 8.9s, bit too fast action, remaining will see how it reacts coming days

$REPL 8.9-9 big zone incoming

$USAR William Blair initiated coverage of USA Rare Earth with an Outperform rating and no price target. USA Rare Earth is one of the few fully integrated rare earth companies, featuring a research facility developing proprietary rare earth extraction and purification technology,

In @FortuneMagazine’s latest robotics commentary, OpenMind Founder @JanLiphardt explores a key question: "How do you trust a robot you've never met?" Only through transparent, enforceable, and human-first standards can we truly build trust with robots. (Full Article Below)

$REPL ~23% SI, days to cover 4.6 fyi

$REPL ~20% locked

$RANI gapped up some

$REPL decent gap : REPL Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma PDUFA April 2026

$SLS just FYI

$HOLX Blackstone, TPG near deal to acquire Hologic, Bloomberg reports

$NVTS don't think it matters cause Blackrock stake in virtually every stock but 11.3M 5.3% stake

TRUMP TO ANNOUNCE SIGNIFICANT TARIFF RELIEF FOR AUTOMAKERS U.S. PRODUCTION -SENIOR U.S. OFFICIAL

$GRAL Data from this study will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premarket approval (PMA) application, along with data from the prevalent screening round of the NHS-Galleri trial. In addition, GRAIL will submit to the FDA a

$GRAL GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings More Than Half of Cancers Detected by Galleri Were Early Stage Approximately

$NVO FDA APPROVES NOVO NORDISK'S ORAL SEMAGLUTIDE FOR CARDIOVASCULAR (CV) RISK REDUCTION IN ADULTS WITH TYPE 2 DIABETES WHO ARE AT HIGH RISK, INCLUDING THOSE WHO HAVE NOT HAD A PRIOR CV EVENT NOVO NORDISK: FDA APPROVES RYBELSUS NOVO NORDISK - SUBMITS APPLICATION FOR WEGOVY ORAL

NVIDIA AND TSMC CELEBRATE FIRST NVIDIA BLACKWELL WAFER PRODUCED IN US

was away from desk most of the session but looks like $RANI didn't hit my stop just yet

$ATAI this insider buy aged well ( https://t.co/VqpOvVVfTG), also Jefferies keeps raising PT https://t.co/Eji7zurI2v

$ATAI Jefferies raised the firm's price target on Atai Life Sciences to $10 from $7 and keeps a Buy rating on the shares. The ATAI-Beckley story "becomes more attractive" with the FDA granting a breakthrough designation to BPL-003, according to the analyst, who expects Atai to